How should acute myeloid leukemia arising from a blastic crisis of chronic myeloid leukemia with central nervous system infiltration be managed?

Management of AML from Blastic Crisis CML with CNS Infiltration

Treat with AML induction chemotherapy according to institutional standards combined with a tyrosine kinase inhibitor (TKI), plus aggressive intrathecal chemotherapy, followed by allogeneic hematopoietic stem cell transplantation (alloHSCT) as soon as remission is achieved.

Treatment Algorithm

1. Immediate Systemic Therapy

• Initiate AML induction chemotherapy following your institution's standard protocol (e.g., "7+3" regimen with cytarabine and anthracycline) 1
• Add TKI therapy - Start at the END of induction chemotherapy, not concurrently, to avoid drug interactions and excessive toxicity 1
  • Use second-generation TKI (dasatinib or nilotinib) or select based on BCR::ABL1 mutation profile if available 1
  • Dasatinib has better CSF penetration than other TKIs, though still insufficient as monotherapy for CNS disease 1
  • If T315I mutation present, use ponatinib 2

Critical timing note: The most recent expert panel guidelines emphasize starting TKI after completing induction chemotherapy rather than simultaneously to minimize toxicity while maintaining efficacy 1.

2. CNS-Directed Therapy

For CNS involvement (blasts in CSF):

• Intrathecal chemotherapy: Administer at least weekly until CSF clears of blasts 1

  • Use triple intrathecal therapy (methotrexate, hydrocortisone, cytarabine) or follow your AML protocol's CNS prophylaxis regimen 3
  • Continue monthly as bridging therapy until transplantation 1

• For CNS-status 3 (>5 blasts/µL in CSF): Individualized intensive approach with at least weekly intrathecal chemotherapy until clearance 1

• Cranial irradiation: Consider TBI-based conditioning with cranial boost if proceeding to transplant with documented CNS involvement 1

Important caveat: No TKI achieves sufficient CSF concentration to safely treat or prevent CNS disease alone, making intrathecal chemotherapy mandatory 1.

3. Consolidation Strategy

• Assess response after first induction cycle:

  • If morphologic complete remission achieved → Proceed directly to alloHSCT
  • If inadequate response → Consider second cycle of chemotherapy only if donor not immediately available 1

• Avoid unnecessary additional chemotherapy cycles that only add toxicity without improving transplant outcomes 1

4. Allogeneic Stem Cell Transplantation

AlloHSCT is the only curative option and should be performed as quickly as possible 4, 2, 5

• Timing: Ideally within 3 months of diagnosis once second chronic phase achieved 1

• Donor search: Initiate immediately at diagnosis

  • Matched sibling or matched unrelated donor (HLA ≥9/10) preferred 1
  • Haploidentical donors acceptable if no matched donor available 6, 2

• Conditioning: Use TBI-based regimen with cranial boost for documented CNS involvement 1

Critical point: Transplantation in active blast crisis has significantly worse outcomes; achieving at least a second chronic phase before transplant is essential 1, 2.

Key Clinical Pitfalls to Avoid

1. Do not delay donor search - Begin HLA typing and donor identification immediately at diagnosis, even before completing induction 1, 2

2. Do not start TKI concurrently with chemotherapy - This increases toxicity without proven benefit; start after induction completion 1

3. Do not rely on TKI alone for CNS disease - Even dasatinib with better CSF penetration requires intrathecal chemotherapy 1

4. Do not over-consolidate with chemotherapy - Additional cycles beyond achieving remission only delay transplant and add toxicity 1

5. Do not omit CNS prophylaxis - Even without overt CNS symptoms, follow AML protocol CNS prophylaxis standards 1

Prognosis and Realistic Expectations

Blast crisis CML with CNS involvement carries a poor prognosis 4, 5. Most long-term survivors are those who achieve remission and proceed to alloHSCT 4, 2, 5. Without transplant, durable remissions are rare despite TKI therapy 4, 5. The combination approach described above offers the best chance for cure, with case reports demonstrating success using intensive CNS-directed chemotherapy with TKI followed by alloHSCT 7.

The evidence strongly supports aggressive multimodal therapy bridging to transplant as the only realistic curative strategy for this high-risk presentation.